{"analyses":[{"ciLowerLimit":"-24.9","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"14.1","groupDescription":"Difference in response rate Arm2- Arm1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Unconditional exact method","paramValue":"-6"},{"ciLowerLimit":"-4.9","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"33.7","groupDescription":"Difference in response rate Arm3 - Arm1","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Unconditional exact method","paramValue":"15"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"7"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"26"}]}],"title":"PR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"54"}],"units":"Participants"}],"description":"Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be \\<10 mm in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters \\[e.g., percent change from Baseline\\]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by BICR as per RECIST, version 1.1.","groups":[{"description":"Participants received dabrafenib 150 mg gelatin capsules BID.","id":"OG000","title":"Part C: Dabrafenib 150 mg"},{"description":"Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.","id":"OG001","title":"Part C: Dabrafenib 150 mg + Trametinib 1 mg"},{"description":"Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.","id":"OG002","title":"Part C: Dabrafenib 150 mg + Trametinib 2 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 19 months)","title":"Part C (Randomized): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response Assessed by Blinded Independent Central Review (BICR)","type":"PRIMARY","unitOfMeasure":"Participants"}